These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 32515018)

  • 1. Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis.
    Chan TLH; Cowan RP; Woldeamanuel YW
    Headache; 2020 Jul; 60(7):1489-1499. PubMed ID: 32515018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
    Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Calcitonin Gene-Related Peptide Receptor Antagonists for Migraine Treatment: A Meta-Analysis.
    Pak K; Kim J; Lee GH; Cho JW; Kim HW
    Eur Neurol; 2022; 85(3):195-201. PubMed ID: 35100579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J; Szok D; Csáti A; Vécsei L
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
    Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
    CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gepants for abortive treatment of migraine: A network meta-analysis.
    Hong P; Tan T; Liu Y; Xiao J
    Brain Behav; 2020 Aug; 10(8):e01701. PubMed ID: 32525262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CGRP - a target for acute therapy in migraine: Clinical data.
    Messina R; Goadsby PJ
    Cephalalgia; 2019 Mar; 39(3):420-427. PubMed ID: 29616830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on gepants for the treatment of chronic migraine.
    Aoh Y; Hou TW; Yang CC; Chang CM; Chen SP; Tsai IJ; Cheng CW; Yang CP
    J Chin Med Assoc; 2024 Apr; 87(4):350-356. PubMed ID: 38349136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CGRP and 5-HT
    Moreno-Ajona D; Chan C; Villar-Martínez MD; Goadsby PJ
    Headache; 2019 Jul; 59 Suppl 2():3-19. PubMed ID: 31291016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
    Haghdoost F; Puledda F; Garcia-Azorin D; Huessler EM; Messina R; Pozo-Rosich P
    Cephalalgia; 2023 Apr; 43(4):3331024231159366. PubMed ID: 36855951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gepants for the treatment of migraine.
    Negro A; Martelletti P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gepants - a long way to cure: a narrative review.
    Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
    Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
    Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CGRP receptor antagonists (gepants).
    Younis S; Latysheva NV; Danilov AB; Ashina M
    Handb Clin Neurol; 2024; 199():51-66. PubMed ID: 38307667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs targeting calcitonin gene-related peptide for the management of migraines.
    Tana C; Cipollone F; Giamberardino MA; Martelletti P
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):233-240. PubMed ID: 37996401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.
    Ha DK; Kim MJ; Han N; Kwak JH; Baek IH
    Clin Drug Investig; 2021 Feb; 41(2):119-132. PubMed ID: 33426614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.